FAQ/Help |
Calendar |
Search |
Today's Posts |
02-11-2014, 01:30 PM | #1 | ||
|
|||
Member
|
Hisamitsu Pharma
Japanese drugmaker Hisamitsu Pharmaceutical’s (TYO: 4530) has announced the results of a Phase II clinical study for a transdermal drug for the treatment of Parkinson’s disease in Japan The efficacy and safety of the HP-3000 (ropinirole hydrochloride) were compared with a placebo in patients with Parkinson’s disease who concomitantly used L-dopa (levodopa). A statistically significant difference was confirmed for improvement in the primary efficacy endpoint compared with the placebo group. The product is a transdermal formulation developed using Hisamitsu’s TDDS (Transdermal Drug Delivery System) technology. Hisamitsu aims to initiate a Phase III clinical study later this year. A company statement said: “We expect the product to be a new option for the treatment of Parkinson’s disease by realizing its long-lasting effect by means of maintaining a stable blood concentration.” A Phase II clinical study of the product started last year for moderate to severe idiopathic restless leg syndrome. Hisamitsu, Parkinson’s disease, HP-3000 |
||
Reply With Quote |
|
|
Similar Threads | ||||
Thread | Forum | |||
NeuroDerm Announces Presentation of ND0612 Phase 1 and Phase 2 Results at the 2013 In | Parkinson's Disease | |||
NeuroDerm Announces Positive Results of a Phase II Study of ND0611 Dermal Patch in Pa | Parkinson's Disease | |||
Biotie Announces Start of Phase 2b Trial of SYN115 in Parkinson's Disease | Parkinson's Disease | |||
Neurologix Announces Successful Phase 2 Trial of Gene Therapy for Parkinson's Disease | Parkinson's Disease | |||
Ceregene announces positive phase 1 results ... | Parkinson's Disease |